Patents Assigned to Trius Therapeutics, Inc.
  • Patent number: 8835445
    Abstract: The present disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R5, R6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 16, 2014
    Assignee: Trius Therapeutics, Inc.
    Inventors: Zhiyong Chen, Christopher J. Creighton, Mark Cunningham, John Finn, Mark Hilgers, Michael Jung, Lucy Aguirre Kohnen, Thanh Lam, Xiaoming Li, Mark Stidham, Les Tari, Michael Trzoss, Junhu Zhang
  • Publication number: 20140206878
    Abstract: Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed.
    Type: Application
    Filed: November 25, 2013
    Publication date: July 24, 2014
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventors: Carrie A. Costello, Jacqueline A. Ware, Robert J. Duguid
  • Publication number: 20140057874
    Abstract: Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula IV: wherein n is a non-negative integer; wherein each Z is an oxazolidinone-containing moiety having antibiotic activity in vivo upon cleaving, wherein M is independently OR1 or NR1R2; wherein R1 and R2 are independently selected from the group consisting of H, an optionally-substituted hydrocarbyl residue or a pharmaceutically acceptable cation; wherein the compound in the dosage form or a pharmaceutical composition is present in an amount effective for treating or preventing an antibacterial infection in a mammalian subject. Methods of preparing and using these dosage forms or pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventors: David Keith Hester, II, Robert J. Duguid, John Finn
  • Patent number: 8604209
    Abstract: Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: December 10, 2013
    Assignee: Trius Therapeutics, Inc.
    Inventors: Jacqueline A Ware, Carrie A Costello, Robert J. Duguid, Douglas Phillipson
  • Publication number: 20130310343
    Abstract: A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
    Type: Application
    Filed: April 22, 2013
    Publication date: November 21, 2013
    Applicant: Trius Therapeutics, Inc.
    Inventors: Katharina Reichenbacher, Robert J. Duguid, Jacqueline A. Ware, Douglas Phillipson
  • Patent number: 8580767
    Abstract: Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula IV: wherein n is a non-negative integer; wherein each Z is an oxazolidinone-containing moiety having antibiotic activity in vivo upon cleaving, wherein M is independently OR1 or NR1R2; wherein R1 and R2 are independently selected from the group consisting of H, an optionally-substituted hydrocarbyl residue or a pharmaceutically acceptable cation; wherein the compound in the dosage form or a pharmaceutical composition is present in an amount effective for treating or preventing an antibacterial infection in a mammalian subject. Methods of preparing and using these dosage forms or pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: November 12, 2013
    Assignee: Trius Therapeutics, Inc.
    Inventors: D. Keith Hester, II, Robert J. Duguid, John Finn
  • Patent number: 8461188
    Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: June 11, 2013
    Assignee: Trius Therapeutics, Inc.
    Inventors: Kenneth F Bartizal, Jeffrey B Locke, Karen Joy Shaw, Philippe G Prokocimer
  • Publication number: 20130102523
    Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.
    Type: Application
    Filed: October 19, 2012
    Publication date: April 25, 2013
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventor: Trius Therapeutics, Inc.
  • Patent number: 8426389
    Abstract: A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi , anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: April 23, 2013
    Assignee: Trius Therapeutics, Inc.
    Inventors: Katharina Reichenbächer, Robert J. Duguid, Jacqueline A. Ware, Douglas Phillipson
  • Publication number: 20130079323
    Abstract: Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 28, 2013
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventors: Christopher J. Creighton, Leslie William Tari, Zhiyong Chen, Mark Hilgers, Thanh To Lam, Xiaoming Li, Michael Trzoss, Junhu Zhang, John Finn, Daniel Bensen
  • Patent number: 8298543
    Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: October 30, 2012
    Assignee: Trius Therapeutics, Inc.
    Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
  • Publication number: 20120238751
    Abstract: Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    Type: Application
    Filed: March 14, 2012
    Publication date: September 20, 2012
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventors: Daniel Bensen, Zhiyong Chen, John Finn, Thanh To Lam, Suk Joong Lee, Xiaoming Li, Douglas W. Phillipson, Leslie William Tari, Michael Trzoss, Junhu Zhang, Felice C. Lightstone, Toan B. Nguyen, Sergio E. Wong, Paul Aristoff, Michael Jung
  • Publication number: 20120136014
    Abstract: The present disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R5, R6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.
    Type: Application
    Filed: June 2, 2011
    Publication date: May 31, 2012
    Applicant: TRIUS THERAPEUTICS, INC.
    Inventors: Zhiyong Chen, Christopher J. Creghton, Mark Cunningham, John Finn, Mark Hilgers, Michael Jung, Lucy Aguirre Kohnen, Thanh Lam, Xiaoming Li, Mark Stidham, Les Tari, Michael Trzoss, Junhu Zhang
  • Patent number: 8021665
    Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: September 20, 2011
    Assignee: Trius Therapeutics, Inc.
    Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
  • Patent number: 7910337
    Abstract: The invention provides a method for generating and selecting drug-sensitizing antisense DNA fragments. In one embodiment, the method includes identifying a gene of interest using knowledge of bacterial physiology, biochemistry, genetics, genomics, and other means. The method includes PCR amplification of a gene of interest using genomic DNA as a template; fragmentation of the DNA by sonication or other means; selecting DNA fragments no longer than 400 base pairs; ligating the DNA fragments into a suitable expression plasmid with a selectable marker; transforming the plasmids containing the DNA fragments into the organism from which the gene of interest originated; and selecting clones from transformed cells that show a phenotypic difference of the clone grown in the presence of the inducer relative to the phenotype in the absence of inducer.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: March 22, 2011
    Assignee: Trius Therapeutics, Inc.
    Inventors: Robert Haselbeck, Mark Hilgers, Karen Shaw, Vickie Brown-Driver, Kedar Gc, John M. Finn, Mark Stidham